Intraocular soluble intracellular adhesion molecule-1 correlates with subretinal fluid height of diabetic macular edema
- PMID: 23619489
- PMCID: PMC4061666
- DOI: 10.4103/0301-4738.111184
Intraocular soluble intracellular adhesion molecule-1 correlates with subretinal fluid height of diabetic macular edema
Abstract
Objective: To investigate the correlations between aqueous concentrations of vascular endothelial growth factor (VEGF), monocyte chemoattractant protein-1 (MCP-1), soluble intracellular adhesion molecule-1 (sICAM-1) and diabetic macular edema (DME).
Materials and methods: VEGF, MCP-1 and sICAM-1 concentrations in aqueous humor samples of 22 patients with DME and 23 patients with cataract of a control group were measured with solid-phase chemiluminescence immunoassay.
Results: Aqueous VEGF (89.2 ± 58.5 pg/ml versus 48.5 ± 27.8 pg/ml, P = 0.006), MCP-1 (684.2 ± 423.4 pg/ml versus 432.4 ± 230.4 pg/ml, P = 0.019) and sICAM-1 (3213.8 ± 2581.6 pg/ml versus 260.2 ± 212.2 pg/ml, P < 0.001) all vary significantly between DME group and control group. Maximum height of submacular fluid measured by Optical coherence tomography (OCT) was significantly associated with aqueous sICAM-1 (r = -0.45, P = 0.034). The maximum height of macular thickness measured by OCT was not significantly associated with either VEGF (P = 0.300), MCP-1 (P = 0.320) or sICAM-1 (P = 0.285).
Conclusions: Our results suggest that sICAM-1 may majorly contribute to the formation of subretinal fluid in DME patients and imply that MCP-1 and sICAM-1 may be the potential therapy targets, besides VEGF.
Conflict of interest statement
Figures





Similar articles
-
Monocyte chemoattractant protein 1, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 in exudative age-related macular degeneration.Arch Ophthalmol. 2010 Oct;128(10):1281-6. doi: 10.1001/archophthalmol.2010.227. Arch Ophthalmol. 2010. PMID: 20937997
-
Role of inflammation in previously untreated macular edema with branch retinal vein occlusion.BMC Ophthalmol. 2014 May 18;14:67. doi: 10.1186/1471-2415-14-67. BMC Ophthalmol. 2014. PMID: 24884703 Free PMC article.
-
Aqueous humor analyses of diabetic macular edema patients with subretinal fluid.Sci Rep. 2021 Oct 25;11(1):20985. doi: 10.1038/s41598-021-00442-z. Sci Rep. 2021. PMID: 34697354 Free PMC article.
-
Changes in aqueous and vitreous inflammatory cytokine levels in diabetic macular oedema: a systematic review and meta-analysis.Acta Ophthalmol. 2022 Feb;100(1):e53-e70. doi: 10.1111/aos.14891. Epub 2021 May 4. Acta Ophthalmol. 2022. PMID: 33945678
-
Review on Recent Trials Evaluating the Effect of Intravitreal Injections of Anti-VEGF Agents on the Macular Perfusion of Diabetic Patients with Diabetic Macular Edema.Rev Recent Clin Trials. 2020;15(3):188-198. doi: 10.2174/1574887115666200519073704. Rev Recent Clin Trials. 2020. PMID: 32427087 Free PMC article.
Cited by
-
Hyperreflective foci as biomarkers for inflammation in diabetic macular edema: Retrospective analysis of treatment naïve eyes from south India.Indian J Ophthalmol. 2021 May;69(5):1197-1202. doi: 10.4103/ijo.IJO_2627_20. Indian J Ophthalmol. 2021. PMID: 33913858 Free PMC article.
-
The role of inflammation in diabetic eye disease.Semin Immunopathol. 2019 Jul;41(4):427-445. doi: 10.1007/s00281-019-00750-7. Epub 2019 Jun 7. Semin Immunopathol. 2019. PMID: 31175392 Review.
-
Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema.JAMA Ophthalmol. 2018 Apr 1;136(4):382-388. doi: 10.1001/jamaophthalmol.2018.0179. JAMA Ophthalmol. 2018. PMID: 29522144 Free PMC article.
-
Systemic Associations with Residual Subretinal Fluid after Ranibizumab in Diabetic Macular Edema.J Ophthalmol. 2017;2017:4834201. doi: 10.1155/2017/4834201. Epub 2017 Jul 27. J Ophthalmol. 2017. PMID: 28819567 Free PMC article.
-
Statement of the German Ophthalmological Society, the German Retina Society, and the Professional Association of Ophthalmologists in Germany on treatment of diabetic macular edema : Dated August 2019.Ophthalmologe. 2021 Jan;118(Suppl 1):40-67. doi: 10.1007/s00347-020-01244-w. Ophthalmologe. 2021. PMID: 33033871 Review. English. No abstract available.
References
-
- Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology. 1984;91:1–9. - PubMed
-
- Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes. 1997;46:1473–80. - PubMed
-
- Campochiaro PA. Targeted pharmacotherapy of retinal diseases with ranibizumab. Drugs Today (Barc) 2007;43:529–37. - PubMed
-
- Ozturk BT, Kerimoglu H, Bozkurt B, Okudan S. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema. J Ocul Pharmacol Ther. 2011;27:373–7. - PubMed
-
- Witkin AJ, Brown GC. Update on nonsurgical therapy for diabetic macular edema. Curr Opin Ophthalmol. 2011;22:185–9. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous